Archives of gynecology and obstetrics · 2003
Safety and efficacy of locally applied imiquimod cream 5% for the treatment of condylomata acuminata of the vulva.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Haidopoulos Dimitrios, Diakomanolis Emmanuel, Rodolakis Alexandros, Vlachos George, Elsheikh Alexandros, Michalas Stylianos
Аннотация
AIM: The aim of the present study was to assess the efficacy and safety of local application of imiquimod cream 5% for managing condylomata acuminata of the vulva in women referred to a tertiary University Hospital centre.
METHOD: From a total of 283 patients referred over a 3-year period, 73(26%) were treated with imiquimod.
RESULTS: Approximately 6% failed to continue therapy due to lack of therapeutic effect whereas 71% experienced total clearance of the lesions and 85% reduction of more than 50% in the size of the condylomata. Forty-three percent of the patients observed complete response in the first 6 weeks of therapy. There were no serious adverse events encountered with mild erythema being the commonest. From the patients who were followed-up for the next 12 weeks from the completion of treatment, 13% presented recurrent warts and were managed by a different mode of therapy.
CONCLUSION: Imiquimod cream 5% seems to be an effective and safe method for treating condylomata acuminata of the vulva resulting possibly in lower recurrence rates than other current therapies.
METHOD: From a total of 283 patients referred over a 3-year period, 73(26%) were treated with imiquimod.
RESULTS: Approximately 6% failed to continue therapy due to lack of therapeutic effect whereas 71% experienced total clearance of the lesions and 85% reduction of more than 50% in the size of the condylomata. Forty-three percent of the patients observed complete response in the first 6 weeks of therapy. There were no serious adverse events encountered with mild erythema being the commonest. From the patients who were followed-up for the next 12 weeks from the completion of treatment, 13% presented recurrent warts and were managed by a different mode of therapy.
CONCLUSION: Imiquimod cream 5% seems to be an effective and safe method for treating condylomata acuminata of the vulva resulting possibly in lower recurrence rates than other current therapies.